These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38167538)

  • 21. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
    Dimitrakopoulou-Strauss A; Strauss L
    Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients.
    Dimitrakopoulou-Strauss A; Pan L; Strauss LG
    Cancer Imaging; 2012 Sep; 12(1):283-9. PubMed ID: 23033440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct inference of Patlak parametric images in whole-body PET/CT imaging using convolutional neural networks.
    Zaker N; Haddad K; Faghihi R; Arabi H; Zaidi H
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4048-4063. PubMed ID: 35716176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual-time point
    Parghane RV; Basu S
    Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitigating SUV uncertainties using total body PET imaging.
    Smith CLC; Zwezerijnen GJC; den Hollander ME; Weijland J; Yaqub M; Boellaard R
    Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1070-1078. PubMed ID: 37953391
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expert consensus on oncological [
    Yu H; Gu Y; Fan W; Gao Y; Wang M; Zhu X; Wu Z; Liu J; Li B; Wu H; Cheng Z; Wang S; Zhang Y; Xu B; Li S; Shi H
    Eur Radiol; 2023 Jan; 33(1):615-626. PubMed ID: 35751696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual-time-point [18F]-FDG PET/CT in the diagnostic evaluation of suspicious breast lesions.
    Caprio MG; Cangiano A; Imbriaco M; Soscia F; Di Martino G; Farina A; Avitabile G; Pace L; Forestieri P; Salvatore M
    Radiol Med; 2010 Mar; 115(2):215-24. PubMed ID: 20017002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
    Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma.
    Lin WY; Tsai SC; Hung GU
    Nucl Med Commun; 2005 Apr; 26(4):315-21. PubMed ID: 15753790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of the long axial field-of-view PET/CT with low-dose [
    Sachpekidis C; Pan L; Kopp-Schneider A; Weru V; Hassel JC; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1158-1167. PubMed ID: 36474125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of FDG PET-CT in differential diagnosis of pleural pathologies.
    Elboga U; Yılmaz M; Uyar M; Zeki Çelen Y; Bakır K; Dikensoy O
    Rev Esp Med Nucl Imagen Mol; 2012; 31(4):187-91. PubMed ID: 23067687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early Diagnosis of Murine Sepsis-Associated Encephalopathy Using Dynamic PET/CT Imaging and Multiparametric MRI.
    Zhu T; Jiang J; Xiao Y; Xu D; Liang Z; Bi L; Yang M; Liang M; Li D; Lin Y
    Mol Imaging Biol; 2022 Dec; 24(6):928-939. PubMed ID: 35612771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric 18F-FDG PET Images in Non-Small Cell Lung Cancer.
    Tixier F; Vriens D; Cheze-Le Rest C; Hatt M; Disselhorst JA; Oyen WJ; de Geus-Oei LF; Visser EP; Visvikis D
    J Nucl Med; 2016 Jul; 57(7):1033-9. PubMed ID: 26966161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual time point fluorodeoxyglucose positron emission tomography/computed tomography in differentiation between malignant and benign lesions in cancer patients. Does it always work?
    Saleh Farghaly HR; Mohamed Sayed MH; Nasr HA; Abdelaziz Maklad AM
    Indian J Nucl Med; 2015; 30(4):314-9. PubMed ID: 26430314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of 18F-FDG PET/CT imaging with different dual time 18F-FDG PET/CT with forced diuresis in clinical diagnosis of prostate cancer.
    Yu L; Huang S; Wu S; Yue J; Yin L; Lin Z
    Medicine (Baltimore); 2023 Jan; 102(2):e32331. PubMed ID: 36637950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and background tissues.
    Povoski SP; Murrey DA; Smith SM; Martin EW; Hall NC
    BMC Cancer; 2014 Jun; 14():453. PubMed ID: 24942656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size.
    Kurland BF; Muzi M; Peterson LM; Doot RK; Wangerin KA; Mankoff DA; Linden HM; Kinahan PE
    J Nucl Med; 2016 Feb; 57(2):226-30. PubMed ID: 26493206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.